



ASX ANNOUNCEMENT

Cann Group Receives \$315k Funding Advance on R&D Refund

16 June 2025 – Cann Group Limited (ASX: CAN) (**Cann** or the **Company**) announced today that it has received a second advance of \$315,552 from Radium Capital, providing early access to the Company's expected Research and Development (R&D) Tax Incentive for FY2025, associated with R&D activities conducted during March and April 2025.

The second advance follows an initial Advance of \$836,469 (relating to R&D activities up until end of February 2025), and is subject to the same commercial terms as announced on 28 April 2025 in respect of that initial Advance.

The total amount borrowed is \$1,152,021, and will be repaid on the date that the rebate from the Company's Research and Development (R&D) Tax Incentive for FY2025 is received, or 31 October 2025 (whichever occurs earlier).

Authorised for release by Steven Notaro, Company Secretary, Cann Group Limited.

For all other information please contact:

Jenni Pilcher
CEO & Managing Director
Cann Group Limited
+61 3 9095 7088
contact@cann grouplimited.com

Steven Notaro
Company Secretary
Cann Group Limited
+61 3 9095 7088
contact@cann grouplimited.com

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is enhancing patients' lives by developing, producing, and supplying innovative cannabis medicines. The Company has research facilities and corporate headquarters in Melbourne and operates a state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. Cann Group also owns Satipharm and its patent-protected capsule technology.

Learn more at: www.cann grouplimited.com | www.satipharm.com